Biotage has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.
Biotage, a supplier of solutions and technology for analytical, medicinal and peptide chemistry, has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.
According to Biotage, ACI has the potential to improve chromatography efficiency in the laboratory. ACI can move users to the endpoint faster. Traditional purification takes more than 15 minutes. With ACI, the time is reduced to 5 minutes. A 250-mg scale laboratory experiment can now be purified in less than 3 minutes on a 10 g column with an ACI enabled Biotage Isolera flash purification system.
"Chemists will now have freedom to work on other things while they let their ACI system do the purification. It is fully automated, reliable and lightning fast, we can completely purify 250 mg of sample in less than 3 minutes, this is quicker than most people take to run the TLC," said Sunil Rana, global product manager, Biotage, in a press release.
Biotage Isolera systems recommend cartridges based on the sample size and programed TLC data; they work out the best solvent gradient based on compound, and provide real time indication of eluting compounds, using UV, ELSD or mass detection. They subtract signal baselines automatically so that chemists can be confident that the correct fractions are collected.
ACI works seamlessly with the Biotage Isolera system. The simple wizard quickly guides chemists through the system, beneficial for new users or those whose expertise or priorities lie in synthesis rather than purification. Existing Biotage Isolera systems can be upgraded to ACI systems. ACI will come as standard on all new production systems.
Source: Biotage
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.